

## RECOMMENDATIONS

In view of our findings, we recommend the following:

- 1- It is critical to understand H.pylori virulence antigens and their relation to different diseases and malignancies.
- 2- There is a need for future research into the pathogenesis of Helicobacter pylori in Hepatitis C virus patients , as seropositivity to specific antigens does not absolutely indicate the relationship with pathogenesis of specific disease.
- 3- We recommend additional investigations with greater number of patients to answer the question on true association of protein CagA and p30 with with leukemic and lypthoma patients Also we recommend further studies on the vacA antigen and its association with malignant diseases.
- 4- Further studies are needed to explore the risk factors that contribute to the high prevalence of H.pylori infection.

## REFERANCES

- 1- The Nobel Prize in Physiology or Medicine 2005". [http:// nobelprize. org/ medicine/laureates/2005/index.html](http://nobelprize.org/medicine/laureates/2005/index.html). Retrieved 2008-08-02.
- 2- Hausen HZ, Infections causing cancer, Wiley-VCH; Weinheim. 2006.
- 3- Marshall BJ, Warren JR (June 1984). "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration". *Lancet* 2006; 1 (8390): 1311–5.
- 4- Liddell HG and Scott R. *A Lexicon: Abridged from Liddell and Scott's Greek-English Lexicon*. Oxford [Oxfordshire]: Oxford University Press. ISBN1966.
- 5- Goodwin et al. Goodwin CS, Armstrong JA, Chilvers T et al..Transfer of *Campylobacter pylori* and *Campylobacter mustelae* to *Helicobacter gen.nov.as Helicobacter pylori comb.nov. and Helicobacter mustelae comb.nov.,* Respectively. *Int J Syst Bacteriol* 1989; 39:397-405.
- 6- Glupczynski Y.: Infection with *Helicobacter pylori* In : Topley and Wilson : *Microbiology & Microbial Infections*, Collier, L,Ballows, A. Sussman, M.(ed), 9<sup>th</sup> edition, Arnold, London Vol 3,ch 30,1998; 581-591
- 7- Versalovic J, Fox JC.:p *Helicobacter* in Murray PR, Baron E J, P faller M A,Temover F C &Yolken R H. *Manual of clinical Microbiology* (7<sup>th</sup>ed) A S M ch1999;727-738
- 8- Geiss G,Suerbaum S. Forsthoff B,leying, H,OpeferkuchW. :Ultrastructure& biochemical studies of the flagellarsheath of *Helicobacter pylori*.*J.Med.Microbiol.*1993;38 :371-377
- 9- Nachamkin I, Skirrow M.B.: *Campylobacter,Arcobacter.& Helicobacter pylori* In: Topley and Wilson : *Microbiology & Microbial Infections*, Collier, L,Ballows, A. Sussman, M.(ed), 9<sup>th</sup> edition, Arnold, London Vol 12,ch1998; 54: 238-1256
- 10- Black JG. :Gastrointestinal diseases caused by bacteria in: *Microbiology Principles & Explorations* (4<sup>th</sup>ed) John Wiley & Sons ch.1999; 22 :647
- 11- Dunn BE,: Serodiagnosis of *Helicobacter Pylori*.In:*Manual of Clinical laboratory immunology* (4<sup>th</sup>ed) : AMS press ch1997; 57 :498-501
- 12- Bode G, Maue F, Dischuneit H,Malferteiner, P. : identification of structures containing polyphosphate in *Helicobacter pylori*.*J.Gen. Microbiol.*1993b; 139: 3029-3033.
- 13- Benaissa M, Babin,Queliard N, Pezennec L, Cenatiempo Y,fauchereJL.:Changes in *Helicobacter Pylori* ultrastructure antigens during conversion from the bacillary to coccoidform.*Infect. Immun.*1996; 64:2333-2335.
- 14- Doig P, Trust TJ.: Identificatiom of surface–exposed outer membrane antigens of *Helicobacter pylori*.*Infect, Immun.*1994; 62: 4526-4533.
- 15- Exner MM, Doig P,Trust TJ, HancockRE.: Isolation & characterization of a family of porin proteins from *Helicobacter pylori*.*Infect, Immun* :1995; 63: 1567-1572.

## References

---

- 16- Aspinall GO, Monteiro MA, Wang HP, Walsh EJ, Moran AP. Lipopolysaccharides of the *Helicobacter pylori* type strain NCTC 11637 (ATCC 43504) Structure of the O antigen chain and core oligosaccharide regions. *Biochemistry* 1996; 35: 2489-2497.
- 17- Skirrow MB.: *Campylobacter and other motile curved Gram –negative rods*: cited from Topley & Wilson's: *Principles of Bacteriology, Virology & Immunity*, 8<sup>th</sup> ed vol.2, *Systematic Bacteriology* 1990;234-240.
- 18- Brown LM, Thomas TL, Ma JL, Chang YS, You WC, Liu WD, Zhang L, Gail MH. *Helicobacter pylori* infection in rural China: exposure to domestic animals during childhood and adulthood. *Scand. J. Infect. Dis.* 2001; 33:686–691.
- 19- Fox JG. Nonhuman reservoirs of *Helicobacter pylori*. *Aliment. Pharmacol. Ther.* 9(Suppl. 2)1995; 93–103.
- 20- Allaker RP, Young KA, Hardie JM, Domizio P, Meadows NJ. Prevalence of *Helicobacter pylori* at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission. *J. Med. Microbiol.* 2002;51:312–317.
- 21- Lu Y, Redlinger TE, Avitia R, Galindo A, Goodman K. Isolation and genotyping of *Helicobacter pylori* from untreated municipal wastewater. *Appl. Environ. Microbiol.* 2002; 68:1436–1439.
- 22- Poms RE, Tatini SR. Survival of *Helicobacter pylori* in ready-to-eat foods at 4 degrees C. *Int. J. Food Microbiol.* 2001;63:281–286.
- 23- Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive *Helicobacter pylori* eradication therapy: experience from a large prospective series. *Gut* 2004; 53:34–37.
- 24- Kuipers EJ, Uytendaele AM, Pena AS, Hazenberg HJ, Bloemena E, Lindeman J, Klinkenberg-Krol EC, Meuwissen SG. Increase of *Helicobacter pylori*-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. *Am. J. Gastroenterol.* 1995; 90:1401–1406.
- 25- Brown LM, Thomas TL, Ma JL, Chang YS, You WC, Liu WD, Zhang L, Gail MH. *Helicobacter pylori* infection in rural China: exposure to domestic animals during childhood and adulthood. *Scand. J. Infect. Dis.* 2001;33:686–691.
- 26- International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 61: schistosomes, liver flukes and *Helicobacter pylori*. International Agency for Research on Cancer, Lyon, France. 1994.
- 27- Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. *Helicobacter pylori* and atrophic gastritis: importance of the cagA status. *J. Natl. Cancer Inst.* 1995; 87:1777–1780.
- 28- El-Omar EM, Carrington M, Chow WH, McColl K E, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; 404:398–402.

## References

---

- 29- Kuipers EJ. Review article: exploring the link between *Helicobacter pylori* and gastric cancer. *Aliment. Pharmacol. Ther.* 1999; 13:3–12.
- 30- Hatchem CY, Clarridge Je, Evans DG, raham DY.: Comparison of agar base: d: media for primary isolation of- *Helicobacter pylori*. *J. Clin. Pathol.* 1995;48:714-716.
- 31- Dent JC, McNutty CA. Evaluation of a new selective medium for campylobacter pylori, *Eur. J. ClinMicrobiol. Infect. Dis*, 1988; 7: 555-8.
- 32- Shakamet MUE, Paski-Kolva S. Evaluation of liquid media for growth of *Helicobacter pylori*. *J. Clin. Microbiol.* 1991; 29(12): 2835-2837.
- 33- Perez-Perez, GI, Rothenbacher D, Brenner H. Epidemiology of *Helicobacter pylori* infection. *Helicobacter* 2004; 9(Suppl. 1):1–6.
- 34- Malaty HM, Graham DY. Importance of childhood socioeconomic, status on the current prevalence of *Helicobacter pylori* infection. 1994.
- 35- Perez-Perez GI, Olivares AZ, Foo FY, Foo S, Neusy AJ, Ng C, Holzman RS, Marmor M, Blaser MJ. Seroprevalence of *Helicobacter pylori* in New York City populations originating in East Asia. *J. Urban Health* 2005; 82:510–516.
- 36- Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. *Clin. Pharmacol. Ther.* 2001; 69:158–168.
- 37- Akopyants NS, Eaton KA, Berg DE. Adaptive mutation and cocolonization during *Helicobacter pylori* infection of gnotobiotic piglets. *Infect. Immun.* 1995; 63:116–121.
- 38- Owen RJ. Bacteriology of *Helicobacter pylori* Belier's *Clin Gastroenterol* 1995; 9: 415-16.
- 39- Taylor D.N, Parsonnet J. Epidemiology & Natural history H. pylori infections. P. 551-564. In M.J. Blaser PF, Ravdin SJ, Greenberg H, Guerrant RL (ed.), *Infections of the gastrointestinal tract*. Raven Press, New York, N.Y. 1995.
- 40- Holcombe C. *Helicobacter pylori*: the African Enigma. *Gut* 1992; 33
- 41- Prescott LM, Harley JP, Klein DA. Microbial diseases and their control. In: *Microbiology* (3<sup>rd</sup> ed). WCB Brawn 1996; 758.
- 42- Song O, Zirnstein GW, Swaminathan B, Gold BD. Pretreatment with urea hydrochloric acid enhances the isolation of *Helocobacter pylori* from contaminated specimens. *Clin Microbial* 2001; 3915; 1967-8.
- 43- Akamitsu T, Tabata K, Hironaga M, Kawakama H, Uyeda M. Transmission of *Helicobacter pylori* infection via flexible fibroptic endoscopy. *Am. J. Infect. Control.* 1996; 24: 396-401.
- 44- Brown LM. *Helicobacter pylori*: epidemiology and notes of transmission. *Epidemiol. Rev.* 2000; 22(2): 283-97.
- 45- Pattinson JR, Groneberg RN, Hotton J, Ridgway GL, Scott G, Wilson APR. *Helicobacter pylori* in: A practical Goide to clinical Bacteriology JohWiliy and Sons, 1995; 31: 156-158.

## References

---

- 46- El-Fiky MAF. (2000): Fresh look on *Helicobacter pylori* M.S Thesis. Internal medicine faculty of Medicine Cairo University.
- 47- Graham DY. *Helicobacter pylori* techniques for clinical diagnosis and basic research. WB Saunder co, Philadelphia. 1996.
- 48- Van Doorn LJ, Figueiredo C, Sana R, Pena AS, Midolo P, Ng EK, Atherton JC, Blaser MJ, Quint W. Expanding allelic diversity of *Helicobacter pylori* VACA. *J. Clin. Microbiol* 1998; 36:2597-2603.
- 49- Gold BD, Doorn LJ, Guarner J, Owens M, Smith DP, Song CO, Wagner HL, Sherman PM, Nola OL, Czinn SJ. Genotypic clinical and demographic characteristics of children and infected with *Helicobacter pylori*, *J Clin Microbiol* 2001; 39(4): 1348-1352.
- 50- Goh KL, Parasakthi N, Ong KK. Prevalence of *H. pylori* infection in endoscopy and non-endoscopy personnel: results of a field survey with serology and 14C urea breath test. *Am. J. Gastroenterol.* 1996; 91(2): 268-270.
- 51- Azuma T. Genetic diagnosis of *H. pylori* strains. (Article in Japanese). *Nippan. Rinsho* 2001; 59(2): 286-90.
- 52- Kulcsarova E, Fazekaova H, Kralovicova J, Buc M, Kolibasova K, Hegyi E. HLA alleles and susceptibility to dermatological disorders associated with *Helicobacter pylori* infection: a significant association to HLA-Cw\* 06. *Folia Biol* 2001; 47(2): 62-5.
- 53- Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive *Helicobacter pylori* eradication therapy: experience from a large prospective series. *Gut* 2004; 53:34–37.
- 54- Kuipers EJ, Uytterlinde AM, Pena AS, Hazenberg HJ, Bloemena E, Lindeman J, Klinkenberg-Knol EC, Meuwissen SG. Increase of *Helicobacter pylori*-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. *Am. J. Gastroenterol.* 1995; 90:1401–1406.
- 55- Brown LM, Thomas TL, Ma JL, Chang YS, You WC, Liu, W D, Zhang L, Gail MH. *Helicobacter pylori* infection in rural China: exposure to domestic animals during childhood and adulthood. *Scand. J. Infect. Dis.* 2001; 33:686–691.
- 56- International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 61: schistosomes, liver flukes and *Helicobacter pylori*. International Agency for Research on Cancer, Lyon, France. 1994.
- 57- Kuipers, E. J. Review article: exploring the link between *Helicobacter pylori* and gastric cancer. *Aliment. Pharmacol. Ther.* 1999; 13:3–12.
- 58- Eidt S, Stolte M, Fischer R. *Helicobacter pylori* gastritis and primary gastric non-Hodgkin's lymphomas. *J. Clin. Pathol.* 1994; 47:436–439
- 59- Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelmann JH, Friedman GD. *Helicobacter pylori* infection and gastric lymphoma. *N. Engl. J. Med.* 1994; 330:1267.

## References

---

- 60- Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. *N. Engl. J. Med.* 2004; 350:213–215.
- 61- Bergman MP, Vandembroucke-Grauls CM, Appelmelk BJ, 'Elios MMD, Amedei A, Azzurri A, Benagiano M, Del G. Prete. The story so far: *Helicobacter pylori* and gastric autoimmunity. *Int. Rev. Immunol.* 2005; 24:63–91.
- 62- Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J. Med. Microbiol.* 1988; 26:93–99.
- 63- Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N, Rappuoli R. Molecular characterization of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc. Natl. Acad. Sci. USA* 1993; 90:5791–5795.
- 64- Ching CK, Wong BC, Kwok E, Ong L, Covacci A, Lam SK. Prevalence of CagA-bearing *Helicobacter pylori* strains detected by the anti-CagA assay in patients with peptic ulcer disease and in controls. *Am. J. Gastroenterol.* 1996; 91:949–953.
- 65- Akopyants NS, Clifton SW, Kersulyte D, Crabtree JE, Youree BE, Reece CA, Bukanov NO, Drazek ES, Roe BA, Berg DE. Analyses of the *cag* pathogenicity island of *Helicobacter pylori*. *Mol. Microbiol.* 1998; 28:37–53.
- 66- Blaser M, Crabtree JE. CagA and the outcome of *Helicobacter pylori* infection. *Am. J. Clin. Pathol.* 1996; 106:565–567.
- 67- Beales ILP, Crabtree JE, Scunes D, Covacci A, and Calam J. Antibodies to CagA protein are associated with gastric atrophy in *Helicobacter pylori* infection. *Eur. J. Gastroenterol. Hepatol.* 1996; 8:645–649.
- 68- Asahi M, Azuma T, Ito S, Ito Y, Suto H, Nagai Y, Tsubokawa M, Tohyama Y, Maeda S, Omata M, Suzuki T, Sasakawa C. *Helicobacter pylori* CagA protein can be tyrosine phosphorylated in gastric epithelial cells. *J. Exp. Med.* 2000; 191:593–602.
- 69- Selbach M, Moese S, Hauck CR, Meyer TF, Backert S. Src is the kinase of the *Helicobacter pylori* CagA protein in vitro and in vivo. *J. Biol. Chem.* 2002; 277:6775–6778.
- 70- Yamazaki S, Yamakawa A, Ito Y, Ohtani M, Higashi H, Hatakeyama M, Azuma T. The CagA protein of *Helicobacter pylori* is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. *J. Infect. Dis.* 2003; 187:334–337.
- 71- Munzenmaier A, Lange C, Glocker E, Covacci A, Moran A, Bereswill S, Baeuerle PA, Kist M, Pahl HL. A secreted/shed product of *Helicobacter pylori* activates transcription factor nuclear factor-kappa B. *J. Immunol.* 1997; 159:6140–6147.
- 72- Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from *Helicobacter pylori*. *J. Biol. Chem.* 1992; 267:10570–10575.
- 73- Atherton JC, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific

- vacA types with cytotoxin production and peptic ulceration. *J. Biol. Chem.* 1995; 270:17771–17777.
- 74- Cover TL, Blanke SR. *Helicobacter pylori* VacA, a paradigm for toxin multifunctionality. *Nat. Rev. Microbiol.* 2005; 3:320–332.
- 75- Munson L, Nesbit JW, Meltzer DG, Colly LP, Bolton L, Kriek NP. Diseases of captive cheetahs (*Acinonyx jubatus jubatus*) in South Africa: a 20-year retrospective survey. *J. Zoo Wildl. Med.* 1999; 30:342–347.
- 76- Aviles-Jimenez F, Letley DP, Gonzalez-Valencia G, Salama N, Torres J, Atherton JC. Evolution of the *Helicobacter pylori* vacuolating cytotoxin in a human stomach. *J. Bacteriol.* 2004; 186: 5182–5185.
- 77- Atherton JC, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types with cytotoxin production and peptic ulceration. *J. Biol. Chem.* 1995; 270:17771–17777
- 78- Montecucco C, de Bernard M. Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of *Helicobacter pylori*. *Microbes Infect.* 2003; 5:715–721.
- 79- Fitchen N, Letley DP, O’Shea P, Atherton JC, Williams P, Hardie KR. All subtypes of the cytotoxin VacA adsorb to the surface of *Helicobacter pylori* post-secretion. *J. Med. Microbiol.* 2005.
- 80- Ilver D, Barone S, Mercati D, Lupetti P, Telford JL. *Helicobacter pylori* toxin VacA is transferred to host cells via a novel contact dependent mechanism. *Cell. Microbiol.* 2004; 6:167–174.
- 81- Bergman MP, Vandenbroucke-Grauls CM, Appelmelk BJ, D’Elios MM, Amedei A, Azzurri A, Benagiano M, Del Prete G. 2005. The story so far: *Helicobacter pylori* and gastric autoimmunity. *Int. Rev. Immunol.* 2005; 24:63–91.
- 82- Burne RA, Chen YM. Bacterial ureases in infectious diseases. *Microbes Infect.* 2000; 2:533–542.
- 83- Contreras M, Thiberge JM, Mandrand-Berthelot MA, Labigne A. Characterization of the roles of NikR, a nickel-responsive pleiotropic autoregulator of *Helicobacter pylori*. *Mol. Microbiol.* 2003; 49:947–963.
- 84- Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ. 1999.
- 85- Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* 1993; 262:1892–1895
- 86- Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of *Helicobacter pylori*. *Proc. Natl. Acad. Sci. USA* 2000; 97:7533–7538.
- 87- Gerhard M, Lehn N, Neumayer N, Boren T, Rad R, Schepp W, Miehle S, Classen M, Prinz C. Clinical relevance of the *Helicobacter pylori* gene for blood-

- group antigen-binding adhesin. Proc. Natl. Acad. Sci. USA 1999; 96:12778–12783
- 88- Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of *Helicobacter pylori* oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123:414–424.
- 89- Prinz C, Schoniger M, Rad R, Becker I, Keiditsch E, Wagenpfeil S, Classen M, Rosch T, Schepp W, Gerhard M. Key importance of the *Helicobacter pylori* adherence factor blood group antigen binding adhesion during chronic gastric inflammation. Cancer Res. 2001; 61:1903–1909.
- 90- Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of *Helicobacter pylori* oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123:414–424
- 91- Ando T, Peek RM, Pride D, Levine SM, Takata T, Lee YC, Kusugami K, van der Ende A, Kuipers EJ, Kusters JG, Blaser MJ. Polymorphisms of *Helicobacter pylori* HP0638 reflect geographic origin and correlate with cagA status. J. Clin. Microbiol. 2002; 40:239–246.
- 92- Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadstrom T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarstrom L, Boren T. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297:573–578.
- 93- Unemo M, Aspholm-Hurtig M, Ilver D, Bergstrom J, Boren T, Danielsson D, Teneberg S. The sialic acid binding SabA adhesin of *Helicobacter pylori* is essential for nonopsonic activation of human neutrophils. J. Biol. Chem. 2005; 280:15390–15397
- 94- Lozniewski A, Haristoy X, Rasko DA, Hatier R, Plenat F, Taylor DE, Angioi-Duprez K. Influence of Lewis antigen expression by *Helicobacter pylori* on bacterial internalization by gastric epithelial cells. Infect. Immun. 2003; 71:2902–2906.
- 95- Bhattacharyya A, Pathak S, Datta S, Chattopadhyay S, Basu J, Kundu M. Mitogen-activated protein kinases and nuclear factor-kappaB regulate *Helicobacter pylori*-mediated interleukin-8 release from macrophages. Biochem. J. 2002; 368:121–129.
- 96- Nomura S, Suzuki H, Masaoka T, Kurabayashi K, Ishii H, Kitajima M, Nomoto K, Hibi T. Effect of dietary anti-urease immunoglobulin on *Helicobacter pylori* infection in Mongolian gerbils. Helicobacter 2005; 10:43–52.
- 97- Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN, Nagler-Anderson C. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter induced gastric atrophy. Nat. Med. 2000; 6:536–542
- 98- Karttunen RA, Karttunen TJ, Yousfi MM, el-Zimaity HM, Graham DY, el-Zaatari FA. Expression of mRNA for interferon-gamma, interleukin-10, and

- interleukin-12 (p40) in normal gastric mucosa and in mucosa infected with *Helicobacter pylori*. *Scand. J. Gastroenterol.* 1997; 32:22–27.
- 99- Meyer F, Wilson KT, James SP. Modulation of innate cytokine responses by products of *Helicobacter pylori*. *Infect. Immun.* 2000; 68:6265–6272
- 100- Hornef MW, Bogdan C. The role of epithelial Toll-like receptor expression in host defense and microbial tolerance. *J. Endotoxin Res.* 2005; 11:124–128.
- 101- Delaney B, Ford A, Forman D, Moayyedi P, M Qume. Initial management strategies for dyspepsia. *Cochrane Database Syst. Rev.* 2005; 2005: CD001961.
- 102- Graham DY, Alpert LC, Smith JL, Yoshimura HH. Iatrogenic *Campylobacter pylori* infection is a cause of epidemic achlorhydria. *Am. J. Gastroenterol.* 1988; 83:974–980.
- 103- Fox JG. The non-*H. pylori* helicobacters: their expanding role in gastrointestinal and systemic diseases. *Gut* 2002; 50:273–283.
- 104- Yamamoto J, Watanabe S, Hirose M, Osada T, Ra C, Sato N. Role of mast cells as a trigger of inflammation in *Helicobacter pylori* infection. *J. Physiol. Pharmacol.* 1999; 50:17–23.
- 105- de Bernard M, Cappon A, Pancotto L, Ruggiero P, Rivera J, DelGiudice G, Montecucco C. The *Helicobacter pylori* VacA cytotoxin activates RBL-2H3 cells by inducing cytosolic calcium oscillations. *Cell. Microbiol.* 2005; 7:191–198.
- 106- Isomoto H, Kawazoe K, Inoue K, Kohno S. Usefulness of the immunological rapid urease test for detection of *Helicobacter pylori* in patients who are reluctant to undergo endoscopic biopsies. *Dig Dis Sci* 2006; 51:2302–5.
- 107- Gobert AP, Bambou JC, Werts C, Balloy V, Chignard M, Moran AP, Ferrero RL. *Helicobacter pylori* heat shock protein 60 mediates interleukin-6 production by macrophages via a Toll-like receptor (TLR)-2. 2004.
- 108- Bliss CM, Golenbock DT, Keates S, Linevsky JK, Kelly CP. *Helicobacter pylori* lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemoattractant protein 1 by human monocytes. *Infect. Immun.* 1998; 66:5357–5363.
- 109- Gobert AP, Bambou JC, Werts C, Balloy V, Chignard M, Moran AP, Ferrero RL. *Helicobacter pylori* heat shock protein 60 mediates interleukin-6 production by macrophages via a Toll-like receptor (TLR)-2. 2004.
- 110- Mandell L, Moran AP, Cocchiarella A, Houghton J, Taylor N, Fox JG, Wang TC, Kurt-Jones EA. Intact gram-negative *Helicobacter pylori*, *Helicobacter felis*, and *Helicobacter hepaticus* bacteria activate innate immunity via Toll-like receptor 2 but not Toll-like receptor 4. *Infect. Immun.* 2004; 72:6446–6454.
- 111- Guiney DG, Hasegawa P, Cole SP. *Helicobacter pylori* preferentially induces interleukin 12 (IL-12) rather than IL-6 or IL-10 in human dendritic cells. *Infect. Immun.* 2003; 71:4163–4166.
- 112- Boncristiano M, Paccani SR, Barone S, Ulivieri C, Patrussi L, Ilver D, Amedei A, D’Elios MM, Telford JL, Baldari CT. The *Helicobacter pylori* vacuolating toxin inhibits T cell activation by two independent mechanisms. *J. Exp. Med.* 2003; 198:1887–1897

- 113- Wang J, Brooks EG, Bamford KB, Denning TL, Pappo J, Ernst PB. Negative selection of T cells by *Helicobacter pylori* as a model for bacterial strain selection by immune evasion. *J. Immunol.* 2001; 167:926–934
- 114- Boncristiano M, Paccani SR, Barone S, Ulivieri C, Patrussi L, Ilver D, Amedei A, D'Elios MM, Telford JL, Baldari CT. The *Helicobacter pylori* vacuolating toxin inhibits T cell activation by two independent mechanisms. *J. Exp. Med.* 2003; 198:1887–1897
- 115- Cammarota G, Cianci R, Grillo RL *et al.* Relationship between gastric localization of hepatitis C virus and mucosa-associated lymphoid tissue in *Helicobacter pylori* infection. *Scand. J. Gastroenterol.* 2002; 37: 1126–32.
- 116- Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? *Lancet.* 2001;357:539–45.
- 117- Fagoonee S, Pellicano R, Rizzetto M, Ponzetto A. The journey from hepatitis to hepatocellular carcinoma: Bridging role of *Helicobacter* species. *Panminerva Med.* 2001;43:279–82.
- 118- Crabtree J. Cytokine responses to *Helicobacter pylori* –induced infection. In: Riecken EO, Zeitz M, Stallmach A, Heise W, editors. *Malignancy and chronic inflammation in the gastrointestinal tract: new concepts.* Lancaster: Kluwer Academic Publishers 1995; 25–36
- 119- El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, *et al.* Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature.* 2000;404:398–402.
- 120- Craig JI, McClelland DB, Ludlam CA. Hematological Malignancies. In: Boon NA, Walker BR, Colledge NR, eds. *Davidson's principles & practice of Medicine* 20<sup>th</sup> edition. ELSEVIER Science Limited 2006; 24:1039-55.
- 121- Saint Francis/Mount Sinai Regional Cancer Center. Childhood Acute Lymphoblastic Leukemia Treatment. Available from: <http://www.stfranciscare.org/saintfrancisdoctors/cancercenter/nci/CancerSummary.aspx?id=CDR258001.xml>. Retrieved 6 March 2013.
- 122- Tracey E, Alam N, Chen W, Bishop J. Cancer in New South Wales (NSW): Incidence and Mortality Sydney, Cancer Institute NSW, November 2008.
- 123- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds.): *WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues.* Lyon, France: International Agency for Research on Cancer; 2008.
- 124- Fletcher CDM, Unni KK, Mertens F (Eds): *WHO Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone.* Lyon, France: International Agency for Research on Cancer; 2002.
- 125- Jeha S & Giles FJ. Acute Myeloid Leukemia. *ASH-SAP* 2007:243-252.
- 126- Fialkow PJ. Clonal origin of human tumors. *Biochim. Biophys. Acta.* 1976; 458 (3): 283–321.
- 127- Fialkow PJ, Janssen JW, Bartram CR. "Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy" . *Blood.* 1991 April 1; 77 (7): 1415–7.

- 128- Jaffe ES. World Health Organization Classification of Tumours - pathology and genetics of tumours of haemopoietic and lymphoid tissues. Lyon: IARC Press. 2001.
- 129- Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer*. 2006; 107:2099-2107.
- 130- Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. *Ann Intern Med*. 1985; 103:620-625.
- 131- Vardiman JW, Harris NL, Brunning RD. "The World Health Organization (WHO) classification of the myeloid neoplasms". *Blood*. 2002; 100 (7): 2292–302.
- 132- Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood* 2010; 116(19):3724-3734.
- 133- Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. *Cancer Causes Control* 2008; 19(4):379-390.
- 134- Bishop J. "The treatment of adult acute myeloid leukemia". *Semin Oncol* 1997; 24 (1): 57–69.
- 135- Bishop JF, Matthews JP, Young GA et al., "A randomized study of high-dose cytarabine in induction in acute myeloid leukemia". *Blood* 1996; 87 (5): 1710–7.
- 136- Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E. "Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party". *Br J Haematol*. 1996; 94 (3): 557–73.
- 137- Fenaux P, Chastang C, Chevret S et al. "A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group". *Blood*. 1999 August 15; 94 (4): 1192–200.
- 138- Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature*. 1997; 388: 539–47.
- 139- Quiros RM, Bui CL. Multidisciplinary approach to esophageal and gastric cancer. *Surg Clin North Am*. 2009; 89:79–96.
- 140- Du MQ, Atherton JC. Molecular subtyping of gastric MALT lymphomas: Implications for prognosis and management. *Gut*. 2006; 55:886–893.
- 141- Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med*. 2002;347:1175–1186.
- 142- Parkin DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer*. 2006;118:3030–3044.
- 143- Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med*. 2002; 347:1175–1186.
- 144- Peek RM, Jr, Blaser MJ. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer*. 2002; 2:28–37.

## References

---

- 145- Schistosomes, liver flukes and *Helicobacter pylori*. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 june 1994, IARC Monogr Eval Carcinog Risks Hum. 1994; 61:1–241.
- 146- Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. *Nat ClinPract Oncol*. 2005; 2:90–7.
- 147- Hausen HZ. Infections causing human cancer. Wiley-VCH; Weinheim. 2006
- 148- Wu XC, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: Anatomic site and histology differences. *Cancer Epidemiology* 2009; 33(5):337–346.
- 149- Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clinical Microbiology Reviews* 2006; 19(3):449–490.
- 150- Parsonnet J, Hansen S, Rodriguez L, et al. *Helicobacter pylori* infection and gastric lymphoma. *New England Journal of Medicine* 1994; 330(18):1267–1271.
- 151- Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T. Gastric MALT lymphoma: A model of chronic inflammation-induced tumor development. *Nature Reviews Gastroenterology & Hepatology* 2010; 7(6):336–346.
- 152- Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose *Helicobacter pylori* infection. *Gastroenterology*. 1995; 109: 136–141.
- 153- Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F, et al. Diagnostic tests for *Helicobacter pylori*: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. *Am J Gastroenterol*. 1996; 91: 2125–2129.
- 154- Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in *Helicobacter pylori* positive patients. *Cochrane Database Syst Rev*. 2006; 2.
- 155- Morris A, Ali MR, Brown P, Lane M, Patton K. *Campylobacter pylori* infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error. *J Clin Pathol*. 1989; 42: 727–732.
- 156- Axon A, Deltentre M, Eriksson S, et al. Guidelines for clinical trials in *Helicobacter pylori* infection. *Gut*. 1997; 41(2):1–23.
- 157- Megraud F, Burette A, Glupczynski Y, et al. Comparison of tests for the assessment of *Helicobacter pylori* eradication: results of a multicentre study using centralised facility testing. *Eur J Gastroenterol Hepatol*. 2000; 12: 629–633.
- 158- Han SW, Flamm R, Hachem CY, et al. Transport and storage of *Helicobacter pylori* from gastric mucosal biopsies and clinical isolates. *Eur J Clin Microbiol Infect Dis* 1995; 14: 349-52.
- 159- Veenendaal RA, Lichtendahl-Bernards AT, Pena AS, et al. Effect of transport medium and transportation time on culture of *Helicobacter pylori* from gastric biopsy specimens. *J Clin Pathol* 1993; 46: 561-3.

## References

---

- 160- Genta RM, Graham DY. Comparison of biopsy sites for the histopathological diagnosis of *Helicobacter pylori*: Atopographic study of *H. pylori* density and distribution. *Gastrointest Endosc* 1994; 40: 342-5.
- 161- Gramley WA, Asghar A, Frierson HF Jr, Powell SM. Detection of *Helicobacter pylori* DNA in fecal samples from infected individuals. *J Clin Microbiol* 1999; 37:2236-40.
- 162- Evans DE, Evans DJ, Lampert HC, Graham DY. Restriction fragment length polymorphism in the adhesin gene *hpaA* of *Helicobacter pylori*. *Am J Gastroenterol* 1995; 90: 1282-8.
- 163- Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S. Sensitive detection of *Helicobacter pylori* by using polymerase chain reaction. *J Clin Microbiol* 1992; 30:192-200.
- 164- Ho SA, Hoyle JA, Lewis FA, Secker AD, Cross D, Maps, et al. Direct polymerase chain reaction test for detection of *Helicobacter pylori* in humans and animals. *J Clin Microbiol* 1991; 29:2543-9.
- 165- Chong SK, Lou Q, Fitzgerald JF, Lee CH. Evaluation of 16SrRNA gene PCR with primers Hp1 and Hp2 for detection of *Helicobacter pylori* *J Clin Microbiol* 1996; 34:2728-30.
- 166- Logan RPH, Dill S, Bauer FE, et al. The European 13C-Urea Breath Test for the detection of *Helicobacter pylori*. *Eur J Gastroenterol Hepatol.* 1991; 3:915–921.
- 167- Klein PD, Graham DY. Minimum analysis requirements for the detection of *Helicobacter pylori* infection by the 13C-urea breath test. *Am J Gastroenterol.* 1993; 88:1865–1868.
- 168- Bazzoli F, Zagari RM, Pozzato P, et al. 13C-urea breath test to quantify *H.pylori* colonisation of gastric mucosa and association with severity of inflammation. *Gastroenterology.* 1994; 105:A180.
- 169- Cacoullis F, Batten JJ, Logan RPH, Karim QN, Walker MM, et al. Quantifying the extent of *Helicobacter pylori* with the 13C-urea breath test. *Gut.* 1991;32:A565
- 170- Prewett EJ, Luk YW, Fraser AG, Lam WM, and Pounder RE. Comparison of one day oral dosing with three bismuth compounds for the suppression of *Helicobacter pylori* assessed by the 13C-urea breath test. *Aliment Pharmacol Ther.* 1992;6:97–102
- 171- Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Baron JH. Changes in the intragastric distribution of *H. pylori* during treatment with omeprazole. *Gut.* 1995; 36:12–16.
- 172- Logan RPH, Gummett PA, Misiewicz JJ, Walker MM, Jameson J, et al. The efficacy of ranitidine bismuth citrate (GR122311X) in the treatment of *Helicobacter pylori* infection. *Gastroenterology.* 1992; 102:A114.
- 173- Logan RPH, Hurlimann S, Gummett PA, Walker MM, Karim QN, et al. How quickly does *Helicobacter pylori* (*H. pylori*) recur after treatment. *Gut.* 1992; 33(1):S3.

## References

---

- 174- Johnson PG, Duggan AE, Olson C. How do two diagnostic tests for *H. pylori* compare to two <sup>13</sup>C-urea breath tests (UBT) in assessment of eradication? *Gut* 1996; 39(2): 118.
- 175- Monteiro L, de Mascarel A, Sarrasqueta AM, et al. Diagnosis of *Helicobacter pylori* infection: noninvasive methods compared to invasive methods and evaluation of two new tests. *Am J Gastroenterol* 2001; 96: 353-8.
- 176- Kosunen TU, Seppala K., Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA and IgM antibody titres after eradication of *Helicobacter pylori*. *Lancet* 1992; 339: 893-5.
- 177- Oeasevic M, Dinic M, Miljkovic B, Otasevic LJ, and, Stojanovic P. Diagnoza *Helicobacter pylori* infekcije *Acta Fac Med Naiss* 2003; 20(1):22-8.
- 178- Lerang F, Haug JB, Moum B, et al. Accuracy of IgG serology and other tests in confirming *Helicobacter pylori* eradication. *Scand J Gastroenterol* 1998; 33: 710-5.
- 179- Cutler AF, Prasad VM, Santogade P. Four-year trends in *Helicobacter pylori* IgG serology following successful eradication. *Am J Med* 1998;105:18-20.
- 180- Monteiro L, de Mascarel A, Sarrasqueta AM, et al. Diagnosis of *Helicobacter pylori* infection: noninvasive methods compared to invasive methods and evaluation of two new tests. *Am J Gastroenterol* 2001; 96: 353-8.
- 181- Hawthorne AB, Morgan S, Westmoreland D, et al. A comparison of two rapid whole-blood tests and laboratory serology, in the diagnosis of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 1999; 11: 863-865.
- 182- Duggan AE, Elliott C, Logan RF. Testing for *Helicobacter pylori* infection: validation and diagnostic yield of a near patient test in primary care. *BMJ* 1999; 319:1236-1239.
- 183- Saunders N J, Peden JF, Hood DW, and Moxon ER. Simple sequence repeats in the *Helicobacter pylori* genome. *Mol. Microbiol.* 1998; 27:1091-1098.
- 184- Moran AP, Knirel YA, Senchenkova SN, Widmalm G, Hynes SO, et al. Phenotypic variation in molecular mimicry between *Helicobacter pylori* lipopolysaccharides and human gastric epithelial cell surface glycoforms. Acid-induced phase variation in Lewis(x) and Lewis(y) expression by *H. Pylori* lipopolysaccharides. *J. Biol. Chem.* 2002; 277: 5785-5795.
- 185- Akopyants NS, Clifton SW, Kersulyte D, Crabtree JE, Youree BE, et al. Analyses of the *cag* pathogenicity island of *Helicobacter pylori*. *Mol. Microbiol.* 1998; 28:37-53.
- 186- Langton SR, Casereo SD. *Helicobacter pylori* associated phospholipase A2 activity a factor in peptic ulcer production. *J Clin Path* 1992; 45:221-4.
- 187- Duan BE, Cohen H, Blaser MJ. *Helicobacter pylori*. *Clin Microbiol Rev* 1997; 10:720-41.
- 188- Axsen WS, Styer CM, Solnick JV. Inhibition of heat shock protein expression by *Helicobacter pylori*. *Microb Pathog* 2009;47:231-236

## References

---

- 189- Takashi M, Tayluchi IT, Yamaguchi, H Osaki T, Kanya S. Studies of the effect of clostridium botulinum in Helicobacter pylori is several test models including gnotobiotic mice. 2000.
- 190- Skamoto I, Igarashi M, Kimura Takagi A, Miwa T, Koga Y. Suppressive effect of lactobacillus gasseri OLL. 2716(LG21) on Helicobacter. J Antimicrobchemother, 2001; 47(5): 709-10.
- 191- Bedwell I, Hotton J, Vara D, MacRobert S, Brown SG. In vitro killing of Helicobacter pylori with photodynamic therapy. Lancet 1990; 335: 289-292.
- 192- Wolfsen H, Wang K, Alquist D, Pittelkow M, Cackerill F. Light densitometry in PDT for Helicobacter pylori. Photo. Dynamic therapy and biomedical lasers. Elsevier science Publishers 1992; 281-285.
- 193- Selgrad M, Malfertheiner P. "New strategies for Helicobacter pylori eradication". *Curr Opin Pharmacol* 2008; 8 (5): 593–7.
- 194- Hoffelner H, Rieder G, Haas R. "Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model". *Int. J. Med. Microbiol.* 2008; 298 (1–2): 151–9.
- 195- Kabir S. "The current status of Helicobacter pylori vaccines: a review *Helicobacter* 2007; 12 (2): 89–102.
- 196- Lee S, Shin Y, Hahm K. "Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection". *Journal of digestive diseases.* 2008.
- 197- Michetti P, Kreiss C, Kotloff TKL, et al. Oral immunization of H. pylori infected adults with recombinant urease and LT adjuvant. *Gastroenterology.* 1997; 112: A1 042-139.
- 198- Thomas JE, Austin S, Dale A, et al. Protection by human milk IgA against Helicobacter pylori infection in infancy. *Lancet* 1993; 342: 121-67.
- 199- Mohaminadi M, Czinn S, Kedline K, NedrudJ. Transfer of Helicoacter- specific Th1 or Th2 cells exacerbates Helicobacter-associated gastritis, but only Th2 cells reduce the magnitude of infection. *Gut* 1996; 39(suppl 2): A45.
- 200- Saldmger PF, Porta N, Waanders GA, et al. Therapeutic immunization against Helicobacter infected 13ALWc mice induce? a switch of the cellular response from Th1 to Th2. *Gastro- enterology* 1997; 11: A108.
- 201- El-Omar EM, Carrington M, Chow WH, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. *Nature* 2001; 412:99.
- 202- Franceschi BS, Plummer M. Infection ransmission and chronic disease models in the study of infection-associated Cancers. *British Journal of Cancer* 2014; 110: 7–11
- 203- Parsonnet J. Bacterial Infection as a Cause of Cancer. *Environ Health Perspect* 1995; 103(Suppl 8):263-268.
- 204- de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 2012; 13: 607–15

## References

---

- 205- Amieva MR, El-Omar EM. Host-bacterial interactions in *Helicobacter pylori* infection. *Gastroenterol.* 2008; 134 :306-323
- 206- Yamaoka Y. Roles of the plasticity regions of *h.pylori* in gastroduodenal pathogenesis. *J.Med, Microbiol* 2008; 57:545-553
- 207- Gisbert JP, Pajares JM. 13C-urea breath test in the diagnosis of *helicobacter pylori* infection. *Aliment pharmacol ther.*2004; 20:1001-1017
- 208- Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of *helicobacter pylori* infection. *Clin. Microbiol. Rev* 2006; 19:449-490
- 209- Nogueira C, Figueiredo C, Carneiro F, Taveira Gomes A, Barreria R, figueira P, Salgado C, Belo L, Peixto A, Bravo JC, Realpe JL, Plaisier AP, VQuint WG, Ruiz B, Carrea P, Van Doorn L-J. *Helicobacter pylori* genotypes may determine gastric histopathology. *AM.J. PARASITOL.* 2001; 158:647-654.
- 210- Van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer WA, Quint WG V1998. Clinical relevance of Cag A, Vac A, ice A status of *H.pylori*. *Gastroenterol* 1998; 115 :5865
- 211- Ogiwara H, Sugimoto M, Ohno T, Vilaichone RK, Mahaehai V, Graham DY, Yamaoka Y. Role of deletion located between the intermediate and the middle regions of the *helicobacter pylori* Vac A gene in cases of gastroduodenal diseases. *J. Clin. Microbiol.* 2009; 47: 3493-3500
- 212- Ine V, Alexandra R, Teresa C, Monica O, Cecilia R. Antigenic Diversity Among Portuguese Clinical Isolates of *Helicobacter pylori*. Blackwell Publishing Ltd, *Helicobacter.* 2011; 16: 153–168
- 213- Peter M, Francis M, Colm A, John A, Anthony T. Management of *Helicobacter pylori* infection-the Maastricht IV/ Florence Consensus Report. *Gut.* 2012 ;61:646.
- 214- Vilaichone RK, Mahachai V, Kositchaiwat C, Graham DY, Yamaoka Y. Relation between seroreactivity to low molecular weight *Helicobacter pylori*-specific antigens and disease presentation. *Clin Diagn Lab Immunol* 2003;10:1025-8.
- 215- Yamaoka Y, Kodama T, Graham DY & Kashima K. Search for putative virulence factors of *Helicobacter pylori*: the low-molecular-weight (33–35 K) antigen. *Dig. Dis. Sci.*1998; 43: 1482–1487.
- 216- Marijke BML. Reynders V, Miendje Deyi, Hafid D, Thomas M. Performance of individual *Helicobacter pylori* antigens in the immunoblot-based detection of *H. pylori* infection. *FEMS Immunol Med Microbiol.* 2012; 352–363.
- 217- El-Masry S, El-Shahat M, Badra M, Aboel-Nour M, Lofty M. *Helicobacter pylori* and hepatitis C in Egyptian patients. *J Glob Infect Dis* 2010; 2(1):4-9.

## الملخص العربي

سجل في مصر العديد من الأبحاث التي تناولت العلاقة بين البكتريا الحلزونية و فيروس (ج) والتي أفادت نتائجها بوجود معدلات عالية من الارتباط بين الإصابة بهذه البكتريا ولإصابة بالفيروس. وفي المقابل يلاحظ ان قلة من الأبحاث قد تناولت رصد تواجد هذه البكتريا في الحالات المصابة بالابيضاض الحاد بالدم وسرطان الغدد الليمفاوية الخبيثة. ولذا فلقد تم تصميم هذه الدراسة لبحث هذا الارتباط ان وجد وذلك عبر البحث عن الأجسام المضادة والتي تنتمي الى اكثر ستة من بين مولدات الاجسام المضادة ضراوة لهذه البكتريا في الحالات عينة البحث عبر الاختبار المعملي الجديد نسبيا والمسمى بالمقايسة المناعية ومن ثم ربط الحالة الأكلينيكية بعلامات التوزيع الوبائي للعوامل الضارية للبكتريا الحلزونية ، اضافة الى اختبار جميع الحالات من حيث تواجد مضادات فيروس ج بها كعامل مخاطر والربط بينهما.

ولقد شملت عينة البحث مائة (١٠٠) مريض من الحالات المترددة على وحدة أمراض الدم بقسم الباطنة في مستشفى جامعة الاسكندرية في الفترة من يونيو ٢٠١٢ وحتى سبتمبر ٢٠١٣. وتم اختيار العينة لفحص المصلى من الحالات المشخصة نهائيا اكلينيكيًا ومعمليا بابيضاض الدم و سرطان الغدد الليمفاوية. ومن الجدير بالذكر ان تشخيص أبيضاض الدم كان قد تم بواسطة اختبار العد اكامل للدم وفحص نخاع في حين ان حالات سرطان الغدد الليمفاوية قد تم تشخيصها عبر خزعة العقدة الليمفاوية. وكذا تم فحص تواجد الأجسام المضادة للبكتريا الحلزونية بواسطة اختبار المقايسة المناعية مع اتباع إرشادات وتعليمات الشركة المصنعة.

استخدم في هذه الدراسة طقم اختبار اسمه لاين للكشف الكمي عن الأجسام المضادة للبكتريا الحلزونية في مصلى الدم البشري من نوع IgG و نوع IgA على التوالي من شركة ( Verotec - Genzyme , USA) وفي المقابل لقد استخدم الاختبار التجاري السريع المعتاد في هذه الحالات مع الاتباع الدقيق لتعليمات الصانع وإرشاداته.

ولقد كشفت نتائج الدراسة ان الأجسام المضادة للجين الملازم للسيتوتوكسين (CagA) كانت سائدة في معظم حالات العينة مع ارتباط ملحوظ بين وجود مولدات الاجسام المضادة للبكتريا الحلزونية (VAC) والأجسام المضادة لفيروس ج في حالات سرطان الغدد الليمفاوية وحالات أبيضاض الدم. ونخلص من هذا ان الاختبارات السريعة والغير مخترقة باستخدام المقايسة المناعية تستطيع بسهولة ودقة الكشف عن الأورام الدموية الخبيثة التي تتسبب فيها مسببات المرض لفيروس ج والبكتريا الحلزونية.

الانتشار المصلى للبكتيريا الحلزونية ومضادات فيروس الالتهاب  
الكبدى سى فى ابيضاض الدم وسرطان الغدد الليمفاوية

## رسالة

مقدمة لكلية الطب - جامعة الإسكندرية  
إيفاءً جزئياً لشروط الحصول على درجة

**الماجستير في الميكروبيولوجيا الطبية والمناعة**

مقدمة من

**باكينام عادل السيد غنيم**

بكالوريوس الطب والجراحة ، الإسكندرية

طبيب حر

مستشفيات جامعة الإسكندرية

قسم الميكروبيولوجيا الطبية والمناعة

كلية الطب

جامعة الإسكندرية

٢٠١٤

# المشرفون

أ.د/ منى جمال الدين مرسى  
أستاذ الميكروبيولوجيا الطبية والمناعة  
كلية الطب - جامعة الإسكندرية

أ.د/ نهله عبد المنعم حامد  
أستاذ الأمراض الباطنه  
كلية الطب - جامعة الإسكندرية

د/ ريم عبد الحميد حرفوش  
أستاذ مساعد الميكروبيولوجيا الطبية والمناعة  
كلية الطب - جامعة الإسكندرية

## المشرف المشارك

د/ هدير احمد عكاشة  
مدرس الميكروبيولوجيا الطبية والمناعة  
كلية الطب - جامعة الإسكندرية